MPH
Epidemiology/Biostatistics
George Washington University
2003
See all Profiles
Faculty
Faculty
Tamaro Syton Hudson, PhD, MPH
Associate Professor
Department/Office
- Pharmacology
School/College
- College of Medicine
Biography
Dr. Hudson is currently an Associate Professor in the College of Medicine at Howard University in the Department of Pharmacology. Dr. Hudson received his Bachelor of Science from Iowa State University in Biology in 1994 and went on to receive a Master of Science in Preventive Medicine from Ohio State University in 2007. Afterwards, he received a PhD from Ohio State University in 2002 where he focused on evaluating the functional differences among isothiocyanates in the rat esophageal tumor model. Following his PhD, Dr. Hudson was selected to complete a prestigious Cancer Prevention Fellowship Program at the National Institute of Health, National Cancer Institute, where he focused on utilizing in vitro and in vivo cancer models to assess the biological activity of bioactive compounds on prostate cancer molecular pathways. At the same time, he completed a Master of Public Health from George Washington University in 2003 where he focused on assessing the degree of agreement between a food frequency questionnaire and 4-day food record as it related dietary fiber intake. After completing his MPH and fellowship he was recruited by Howard University Cancer Center in 2007 as an Assistant Professor from the U54 grant research program. Since joining Howard faculty, Dr. Hudson has integrated his research focus by identifying novel signature biomarkers that could have a significant impact on both the diagnosis and targeted treatment of prostate cancer with the evaluation of new chemopreventive strategies which have been evaluated in Phase I and Phase II clinical trials. As important, Dr. Hudson received the first five year VA-HBCU Research, Scientist, and Training grant that focused on developing a biomarker-based risk prediction model for prostate cancer. After the VA grant Dr. Hudson was able to secure several grants, P20, DOD, and IRONMAN. Dr. Hudson serves on several University committees and has many peer-reviewed publications. Certainly, Dr. Hudson research interest continues to expand as he tries to build collaborations that will broaden across disciplines that could help him make an impact in translational research.
Education & Expertise
Education
PhD
Cancer Chemoprevention
The Ohio State University
2002
MS
Preventive Medicine
The Ohio State University
1997
BS
Biology/African American Studies
Iowa State University
1994
Expertise
Associate Professor-Tenured
College of Medicine
Department of Pharmacology
Washington DC
Research Interest: Establish novel gene patterns in men with lethal Prostate cancer.
Academics
Academics
Research Method Course
The Lecture/Laboratory course is designed to introduce graduate students to the basic principles of research in pharmacology, to introduce them to modern techniques and instrumentation used by the research pharmacologist and to acquaint them with institutional processes/procedures that must be considered in a research environment. Emphasis will be on pharmacological techniques used for data acquisition in experiments, which measure physiological, biochemical/biophysical and behavioral responses of animals/tissues/cells to drugs. The laboratory component will be hands-on and will illustrate concepts and methods discussed during the lectures. Each Lecturer will provide learning objectives for each topic and reading assignments. The semester grade will be based on class participation and three exams and a final examination.
Research
Research
Specialty
Prostate Cancer and FXTASFunding
Status: Active
Project Number (Principal investigator): Tamaro Hudson, PhD, PI
Source: Prostate Cancer Clinical Trial Consortium, LLC
Title of Project: IRONMAN: International Registry for Men with Advanced Prostate Cancer
Dates Approved: 8-1-2022- 08-30-2025
Annual Direct Costs/Percent Effort: $134,756
Role: Primary Investigator (PI).
Goal: Register African American men with advance prostate cancer.
Project Number (Principal investigator): Tamaro Hudson, PhD, PI
Source: Howard-Georgetown P20
Title of Project: Characterizing driver mutations and their interaction with the tumor microenvironment to improve clinical management of aggressive prostate cancer in African American men
Dates Approved: 9-1-2021- 08-30-2023
Annual Direct Costs/Percent Effort: $120,000
Role: Primary Investigator (PI).
Goal: Characterize gene mutation patterns for African American men with prostate cancer.
Status: Active
Project Number (Principal investigator): Primary Investigator
Source: DOD
Title of Project: The Genomic Landscape of Papillary Renal Cell Carcinoma Arising In Arising In African American Patients
Dates Approved: 09-1-2021- 08-31-2022
Annual Direct Costs/Percent Effort: $100,000
Role: PI.
Goal: Develop gene patterns for African Americans with renal cell carcinoma.
Related Articles
CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-α) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE)
The influence of Homeobox transcription factor in breast cancer.
The International Fragile X Premutation Registry: building a resource for research and clinical trial readiness
The article highlights the importance of FXTAS researchers of accessing the registry.
Annexin 2 protein expression is associated with breast cancer subtypes in African American women
The article demonstrates the importance of annexin 2 expression in breast cancer subtypes.
Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40
Influence of muscadine grape skin extract inhibitory effects on prostate cancer growth.